Properties and benefits investigated
Spadin-derived TREK-1 potassium-channel inhibition; neuronal-signaling and antidepressant-like behavior research in preclinical models. These findings do not establish treatment of depression in humans.
AVITUS RESEARCHPE22-28
Cognitive
PE22-28
Spadin-derived peptide studied in TREK-1 channel models.
- Research category
- Cognitive
- Intended context
- Laboratory research only
For research use only. Not for human or veterinary use. No claims of safety, efficacy or therapeutic benefit.
Evidence and limitations
The cited findings are preclinical (cells or animals), not demonstrated therapeutic benefits in people.
References
PMID: 28955242
Product specifications.
Contact the Avitus team to confirm available presentations, product specifications and pricing for your research requirements.